Form 4: CYTK CEO Sells Shares for Tax Obligations

Cytokinetics CEO Robert I. Blum reported the disposition of 5,930 common shares at $65.02 each to cover tax liabilities, as part of a pre-arranged plan.

Summary

• Robert I. Blum, President & CEO and Director of Cytokinetics Inc. (CYTK), reported a transaction involving company common stock.
• On December 3, 2025, Mr. Blum disposed of 5,930 shares of common stock.
• The shares were disposed of at a price of $65.02 per share.
• This transaction was coded "F," indicating it was for the payment of tax liability incident to the vesting of a restricted stock award or the exercise of a stock option.
• The transaction was made pursuant to a Rule 10b5-1(c) pre-arranged plan.
• Following this transaction, Mr. Blum directly beneficially owns 350,202 shares of common stock.
• Additionally, 2,083 shares are indirectly owned by The Bridget Blum 2003 Irrevocable Trust, and another 2,083 shares by The Brittany Blum 2003 Irrevocable Trust.

Sentiment

Score: 5

Explanation: The filing reports a routine, non-discretionary insider transaction for tax purposes, which is neutral in sentiment. It does not indicate any significant positive or negative operational or financial news for the company.

Positives

• The transaction was executed under a Rule 10b5-1(c) plan, indicating it was pre-scheduled and not a discretionary sale based on new, non-public information.

Negatives

• A reduction in direct beneficial ownership by a key executive, even for tax purposes, could be perceived negatively by some investors, though it is a common practice.

Future Outlook

NA

Industry Context

This is a routine insider transaction for tax purposes, common across all industries for executives receiving equity compensation. It does not provide specific industry context.

Comparison to Industry Standards

• This type of transaction (shares sold to cover tax obligations upon vesting/exercise) is a standard practice for executives in publicly traded companies across various industries, including biotechnology.
• It is a non-discretionary sale and is typically pre-arranged under a 10b5-1 plan to avoid accusations of trading on inside information.
• No specific comparable companies or projects are relevant here as it's a personal transaction disclosure.

Related Party Transactions

• Indirect beneficial ownership by The Bridget Blum 2003 Irrevocable Trust (2,083 shares) and The Brittany Blum 2003 Irrevocable Trust (2,083 shares) are disclosed, indicating related party holdings.

Stakeholder Impact

• Shareholders: The transaction is a routine tax-related sale by a key executive, which is generally not seen as a significant indicator of company performance or management's confidence. The pre-arranged nature (10b5-1 plan) mitigates concerns about discretionary selling.
• Employees, Customers, Suppliers, Creditors: No direct impact from this specific transaction.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary sale of shares by the CEO to cover tax obligations, executed under a pre-arranged 10b5-1 plan. Such transactions are common and do not typically reflect a change in management's outlook on the company's future prospects or fundamental value. Therefore, based solely on this filing, there is no new information to warrant a change in investment thesis, and a 'hold' recommendation is appropriate.

Keywords

Cytokinetics, CYTK, Robert I. Blum, Insider Trading, Form 4, Stock Sale, Tax Liability, CEO, Director, Beneficial Ownership, 10b5-1 Plan